| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(19)32995-2 |
| P698 | PubMed publication ID | 31982067 |
| P2093 | author name string | Dick de Zeeuw | |
| Hans-Henrik Parving | |||
| Hiddo J L Heerspink | |||
| P2860 | cites work | Avosentan for overt diabetic nephropathy | Q33702404 |
| Predictors of congestive heart failure after treatment with an endothelin receptor antagonist | Q37621556 | ||
| Rationale and protocol of the Study of Diabetic Nephropathy with Atrasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy | Q48098900 | ||
| Is Doubling of Serum Creatinine a Valid Clinical ‘Hard’ Endpoint in Clinical Nephrology Trials | Q61873319 | ||
| Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | Q63170509 | ||
| GFR decline as an end point in trials of CKD: a viewpoint from the FDA | Q86102906 | ||
| Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial | Q93161172 | ||
| P433 | issue | 10220 | |
| P921 | main subject | chronic renal insufficiency | Q736715 |
| P304 | page(s) | 270 | |
| P577 | publication date | 2020-01-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Atrasentan in patients with diabetes and chronic kidney disease - Authors' reply | |
| P478 | volume | 395 |
Search more.